Acadia Pharma (ACAD) – Analyst EPS View
-
Acadia Pharmaceuticals (ACAD) Earnings Preview: Mizuho Sees Q1 Nuplazid Sales of $120M, Hopes to Hear Updates on Review of Nuplazid for Alzheimer's, Reiterates Neutral Rating
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at Needham & Company
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ACAD Stock Lookup